Search research articles
Contact Us
Filters
Showing results (61-70 of 176) with videos related to
Page
of 18
Sort By:
Hematological Oncology
|
October 7, 2017
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Florence Ranchon, Nicolas Vantard, Emilie Henin, et al.
Human Pathology
|
August 24, 2014
Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis
Luc Xerri, Emmanuel Bachy, Bettina Fabiani, et al.
Haematologica
|
September 5, 2007
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
Franck E Nicolini, Sandrine Hayette, Selim Corm, et al.
Hematological Oncology
|
May 4, 2018
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes
Lauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
Emmanuel Bachy, Pauline Brice, Richard Delarue, et al.
Leukemia
|
January 15, 2024
Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos
Manon Zala, Boris Lipinski, Clélia Costechareyre, et al.
The American Journal of Surgical Pathology
|
July 15, 2021
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation
Alexis Trecourt, Claire Mauduit, Vanessa Szablewski, et al.
Blood Advances
|
July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Kai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Haematologica
|
May 7, 2013
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
Emmanuel Bachy, Roch Houot, Franck Morschhauser, et al.
British Journal of Haematology
|
June 22, 2021
Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies
Lucile Bussot, Simon Chevalier, Justine Cristante, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 176) with videos related to
Sort By:
Page
of 18
Hematological Oncology
|
October 7, 2017
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Florence Ranchon, Nicolas Vantard, Emilie Henin, et al.
Human Pathology
|
August 24, 2014
Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis
Luc Xerri, Emmanuel Bachy, Bettina Fabiani, et al.
Haematologica
|
September 5, 2007
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
Franck E Nicolini, Sandrine Hayette, Selim Corm, et al.
Hematological Oncology
|
May 4, 2018
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes
Lauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte
Emmanuel Bachy, Pauline Brice, Richard Delarue, et al.
Leukemia
|
January 15, 2024
Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos
Manon Zala, Boris Lipinski, Clélia Costechareyre, et al.
The American Journal of Surgical Pathology
|
July 15, 2021
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation
Alexis Trecourt, Claire Mauduit, Vanessa Szablewski, et al.
Blood Advances
|
July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Kai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Haematologica
|
May 7, 2013
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
Emmanuel Bachy, Roch Houot, Franck Morschhauser, et al.
British Journal of Haematology
|
June 22, 2021
Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies
Lucile Bussot, Simon Chevalier, Justine Cristante, et al.
Page
of 18